samedi 24 octobre 2020


Tuesday, June 13th 2017 at 8:01pm UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company
pioneering the discovery and development of medicines to control the
expression of disease-driving genes, today announced its participation
at the JMP Securities Life Sciences Conference, including in a panel
discussion, as follows:

JMP Securities Life Sciences Conference
Date: Tuesday, June
20
Panel Title: Epigentics and Transcriptional Control –
Regulating the Regulators

Panel Time: 11:00-11:55 a.m. ET
Location:
The St. Regis New York, 2 East 55 Street, New York, NY

About Syros Pharmaceuticals
Syros Pharmaceuticals is
pioneering the understanding of the non-coding region of the genome to
advance a new wave of medicines that control expression of
disease-driving genes. Syros has built a proprietary platform that is
designed to systematically and efficiently analyze this unexploited
region of DNA in human disease tissue to identify and drug novel targets
linked to genomically defined patient populations. Because gene
expression is fundamental to the function of all cells, Syros’ gene
control platform has broad potential to create medicines that achieve
profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is
advancing a growing pipeline of gene control medicines. Syros’ lead drug
candidates are SY-1425, a selective RAR? agonist in a Phase 2 clinical
trial for genomically defined subsets of patients with acute myeloid
leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7
inhibitor in a Phase 1 clinical trial for patients with advanced solid
tumors, including transcriptionally dependent cancers such as triple
negative breast, small cell lung and ovarian cancers. Led by a team with
deep experience in drug discovery, development and commercialization,
Syros is located in Cambridge, Mass.

Contacts

Media Contact:
Syros Pharmaceuticals
Naomi Aoki,
617-283-4298
naoki@syros.com
or
Investor
Contact:

Stern Investor Relations, Inc.
Hannah
Deresiewicz, 212-362-1200
hannahd@sternir.com

Source: Syros Pharmaceuticals

Étiquettes : , , , , , , , , , , ,